At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Apr 3, 2026 at 16:02 ET
RIGEL PHARMACEUTICALS INC filed a Definitive Additional Materials (DEFA14A) form, which is supplementary proxy solicitation material related to a shareholder vote. The documents provided are primarily technical SEC filing headers and do not contain substantive information about the vote, such as what is being voted on, the outcome, or management's position. This is a routine administrative filing.
- The filing is a DEFA14A, which is Definitive Additional Materials for a proxy statement.
- The documents provided are technical SEC headers and a graphic, not the substantive proxy statement content.
- The filing is routine and administrative in nature.
- No information about the vote, candidates, or issues is available in the provided documents.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access